Rocket Pharmaceuticals Expects $279.4 Million To Carry Operations Past Planned Danon Trial Readout

Conditional access to more loans could fund operations into 2029, while commercial preparations add to administrative spending.

Share
Rocket Pharmaceuticals Expects $279.4 Million To Carry Operations Past Planned Danon Trial Readout

Rocket Pharmaceuticals, which develops gene therapies for inherited heart disease, expects its approximately $279.4 million in cash and investments to fund operations into the third quarter of 2028, beyond its planned mid-2028 Danon disease trial readout. Thursday’s earnings release, accompanying an SEC filing, put additional borrowing-dependent funding into 2029 within reach.

The Borrowing Behind The Cash

Rocket’s September 30 cash, cash equivalents and investments included an initial $35 million loan draw. The balance compared with $188.9 million at December 31, 2025.

The company announced an up-to-$150 million facility with lender Hercules Capital on October 6 to finance the Danon study and other cardiovascular programs. Beyond the initial draw, Rocket may request $35 million during specified windows; another $30 million depends on a Danon clinical milestone, and $50 million requires Hercules’ investment committee approval.

Rocket said funding into 2029 depends on satisfying borrowing requirements, when and how much it draws, and operating spending. Its current cash forecast rests on its existing operating plan.

Research Cuts, Commercial Costs

Rocket’s third-quarter net loss narrowed to $49.2 million, or $0.43 per share, from $50.3 million, or $0.45 per share, a year earlier. Research spending declined to $31.2 million from $34.1 million, while administrative spending increased to $19.8 million from $18.4 million.

Rocket attributed the research decline mainly to lower staffing-related pay, manufacturing and development costs, and depreciation. Compensation fell $3.5 million, manufacturing and materials costs fell $1.9 million, and depreciation fell $1.2 million. Laboratory spending and professional fees each increased $1.4 million, with clinical-trial costs up $0.6 million.

The company attributed the administrative increase primarily to $3.4 million more in post-marketing commitments and $0.6 million more in commercial preparations. Lower staffing-related compensation and legal costs offset part of those increases.

KRESLADI, its gene therapy for children with severe leukocyte adhesion deficiency-I, reached commercial readiness on October 1. Two treatment centers were ready to start patient onboarding, with an external manufacturing network in place. The therapy has accelerated approval; continued approval may depend on follow-up evidence of clinical benefit.

Danon Dosing Sets The Timeline

Rocket’s gene therapies deliver functioning genes into patients’ cells using modified viruses. Its cardiovascular pipeline targets Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy.

On September 15, Rocket announced FDA alignment on a revised dose and a 12-patient pivotal Danon trial intended to support potential accelerated approval. The first three patients treated under the modified protocol count toward that population.

At the 12-month assessment, at least seven patients must meet both goals: sufficient LAMP2 protein expression in heart muscle and a reduction of at least 10% in left ventricular mass index.

Gaurav Shah, Rocket’s chief executive officer, said Thursday, “our priority is to complete dosing by mid-2027.”

Rocket has begun dosing adults with RP-A701 in an early-stage BAG3 study testing safety, biological activity and preliminary effectiveness. The European Commission granted the therapy orphan designation on October 20. Its early-stage PKP2 study remains open for enrollment, with FDA discussions continuing about a potential pivotal study.

Rocket anticipates headline results from the pivotal Danon trial in mid-2028—the clinical milestone its current cash forecast is expected to cover.

Sources

More on Rocket Pharmaceuticals

All Rocket Pharmaceuticals (RCKT) coverage →